These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29285488)

  • 1. Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes.
    Aronow WS; Shamliyan TA
    Ann Transl Med; 2017 Dec; 5(23):455. PubMed ID: 29285488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure targets for hypertension in patients with type 2 diabetes.
    Aronow WS; Shamliyan TA
    Ann Transl Med; 2018 Jun; 6(11):199. PubMed ID: 30023362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS; Shamliyan TA
    Am J Ther; 2020; 27(3):e270-e285. PubMed ID: 30277905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
    Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapié CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Jüni P
    J Am Heart Assoc; 2021 Sep; 10(18):e019918. PubMed ID: 34514812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
    Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
    Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
    Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.
    Aronow WS; Shamliyan TA
    Ann Transl Med; 2018 Apr; 6(8):147. PubMed ID: 29862236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
    Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
    Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
    Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
    Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockers for hypertension.
    Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.